Floatz logo

Davunetide

Predicted Tauopathies, Including

University of California, San Franciscoprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Predicted Tauopathies, Including cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Columbia University
Phase 2BB
Donanemab
Eli Lilly and Company
Phase 3B
NA 831
Biomed Industries, Inc.
Phase 2B
Jaci-35.054
AC Immune SA
Phase 1/2CCC
Aci-35.030
AC Immune SA
Phase 1/2CCC

View all 14 →

Same molecule, other indications

Davunetide is also rated in:

cognitive disorderDormant
B
Indicative ·
57 / 100
View asset →
schizophreniaDormant
CCC
Indicative ·
51 / 100
View asset →
progressive supranuclear palsyDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →